-
Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal
•
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation agreement with Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), securing exclusive commercialization rights for Austedo (deutetrabenazine) in mainland China. Austedo, a vesicle monoamine transporter 2 (VMAT2) inhibitor, received its initial approval in the U.S. in 2017…
-
Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in China for its proprietary drug, tegileridine, indicated for the management of moderate to severe pain following abdominal surgery. This milestone marks the drug as the nation’s inaugural Category 1 opioid analgesic developed indigenously, highlighting a…
-
Jiangsu Nhwa Pharmaceutical Gets NMPA Green Light for Schizophrenia Drug Trial
•
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for its Category 1 chemical drug, NH300231, which is intended for the treatment of schizophrenia. This next-generation atypical antipsychotic drug is characterized as…
